Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mandelic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL7279536 | 0.93 | LMNA (0.90) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL1050 | 0.93 | LMNA (1.00) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL165161 | 0.93 | LMNA (1.00) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL21647917 | 0.93 | LMNA (1.00) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL29777368 | 0.93 | LMNA (1.00) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL255601 | 0.93 | LMNA (1.00) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL5313046 | 0.93 | LMNA (1.00) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL1275427 | 0.91 | LMNA (0.86) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL3934174 | 0.90 | LMNA (0.95) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL9051446 | 0.90 | LMNA (0.95) | LMNAMAPK1HPGDCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-03-05 | — | — | US | disclosed |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-01-29 | — | — | US | disclosed |
| WO-2025224069-A1 | CO-CRYSTALS OF FINERENONE, PECAVAPTAN, AND SGLT2 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-30 | — | — | WO | disclosed |
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER HEALTHCARE PHARMACEUTICALS INC. | 2025-10-02 | — | — | US | disclosed |
| US-20240391873-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-11-28 | — | — | US | disclosed |
| EP-4387673-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2024-06-26 | — | — | EP | disclosed |
| CN-117957021-A | Process for preparing pegylated adrenomedullin, intermediates therefor and uses thereof | 拜耳公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230364245-A1 | PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USE | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20230201174-A1 | COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| EP-4126062-A1 | LIQUID PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USE | Bayer Aktiengesellschaft (DE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115666654-A | Pharmaceutical formulations polyethylene glycol based prodrugs of adrenomedullin and uses | 拜耳公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115484987-A | Liquid pharmaceutical formulations polyethylene glycol based adrenomedullin prodrugs and uses | 拜耳公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021214023-A1 | COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3900722-A1 | COMBINATION OF FINERENONE AND PECAVAPTAN FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | Bayer AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021198328-A1 | PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198327-A1 | LIQUID PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-07 | — | — | WO | disclosed |
| US-8664428-B2 | Method for producing (2,4-dimethylbiphenyl-3-yl)acetic acids, the esters thereof and intermediate compounds | BAYER CROPSCIENCE AG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | DDC, DDT, PAH | ESR2 3510/4885LMNA 2936/4885MAPK1 2095/4885 |
| US-20230364245-A1 | PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USE | ADM2, AREG, CCL11 | ESR2 3291/4885LMNA 1432/4885MAPK1 2408/4885 |
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | ESR2 2683/4885LMNA 240/4885MAPK1 3349/4885 |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | ESR2 2683/4885LMNA 240/4885MAPK1 3349/4885 |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | ESR2 1835/4885LMNA 669/4885MAPK1 892/4885 |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | ESR2 2002/4885LMNA 649/4885MAPK1 1108/4885 |
| US-20230201174-A1 | COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | SLC5A2, SLC5A1, REN | ESR2 856/4885LMNA 2239/4885MAPK1 1170/4885 |
| US-20240391873-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | ADM2, HAMP, SERPINC1 | ESR2 2274/4885LMNA 659/4885MAPK1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.